Drugs and patents in ATC class S01E - ANTIGLAUCOMA PREPARATIONS AND MIOTICS

Last updated: June 7, 2026

Global demand for ATC S01E (antiglaucoma preparations and miotics) is shaped by (1) glaucoma prevalence and aging demographics, (2) high preference for once-daily or combination eye drops that improve adherence, (3) payer pressure toward generics and therapeutically equivalent products, and (4) a patent landscape that remains concentrated in small molecule glaucoma mechanisms (prostaglandin analogs, ROCK inhibitors, Rho-kinase pathways, carbonic anhydrase inhibitors, beta-blockers) and in formulation and dosing patents that extend exclusivity even after primary compound patents expire.

Patent activity in the class clusters into four enforceable buckets that matter for generic and biosimilar-like risk modeling in ophthalmology: active pharmaceutical ingredient (API) patents, method-of-use and regimen patents (including dosing frequency and administration sequences), formulation and device-adjacent patents (preservative systems, osmolarity/pH, viscosity, particle technologies, and delivery systems), and manufacturing/controls patents that can block “design-around” routes.

Below is a structured market and IP map for S01E, with the highest-yield focus on what typically blocks market entry: Orange Book-controlled drug listings, patent estates tied to formulation and method-of-use, and Paragraph IV incentives where the originator’s remaining listed patents create time-to-launch friction.

What patents protect ATC S01E antiglaucoma eye drops and miotics?

Patents protecting S01E products generally fall into predictable claim families. The legal and commercial leverage depends on whether remaining listed patents cover the product as marketed (same active, same strength, same dosage form, and often similar formulation or dosing).

Which patent types dominate glaucoma and miotic exclusivity?

Core composition-of-matter (MoC) for APIs
- Prostaglandin analogs and related derivatives
- Rho-kinase inhibitors and related scaffolds
- Carbonic anhydrase inhibitor derivatives
- Beta-blockers with ophthalmic dosing optimizations
- Miotics (including older agents and newer prodrug approaches where applicable)
Method-of-use (MoU) and treatment regimen claims
- Lowering intraocular pressure (IOP) endpoints
- Specific dosing frequency (once-daily vs twice-daily)
- Combination regimens, including switching or sequencing
Formulation patents
- Preservative system changes (or preservative-free formats)
- pH, buffering capacity, tonicity, viscosity agents
- Stabilization of actives prone to degradation
- Controlled-release or sustained-utility formulations
- Combination formulation-specific patents (fixed-dose combinations)
Manufacturing and process/controls
- Mixing/filtration steps, sterilization and aseptic processing
- Impurity profiles and specifications
- Nanoparticle or particle engineering processes where present

How many patents cover a typical S01E product?

Patent estates for major glaucoma products often include dozens of US patent publications and several “listed” Orange Book patents (with variable remaining term). Listed patents are the ones that drive generic timing through Paragraph IV and settlement leverage.

Featured-snippet answer: The highest-probability blockers for generic entry in S01E are often formulation and method-of-use patents that remain listed after MoC expiration, because they align more directly with what the FDA-approved label permits.

How does the S01E patent estate affect generic entry and Paragraph IV challenges?

S01E generic entry typically runs into two structural constraints:

Many glaucoma drugs are reformulated for tolerability (preservative changes, viscosity and pH optimization), so generics must replicate more than just the API.
Orange Book listing practices can leave multiple active patents late into the life cycle.

What are the common triggers for Paragraph IV in antiglaucoma eye drops?

Waiting for the last Orange Book listed patent to expire for the same strength and dosage form.
Filing Abbreviated New Drug Applications (ANDAs) that rely on bioequivalence but differ in formulation or device, while still being tested against listed patents.
Contesting listed patents via Paragraph IV when there is plausible invalidity or non-infringement.

What settlement terms are typical in ophthalmic glaucoma litigation?

Settlements often include:

Agreed “launch date” delays that extend beyond the contested patent expiry based on negotiated risk.
Design-around commitments that constrain generic formulation or dosing frequency.
Stipulated covenants not to market before a specific date.

The economics are usually driven by how many years of exclusivity remain once the last listed patent expires and whether additional unlisted patents still pose litigation risk.

When do major S01E drugs lose exclusivity, and what timelines drive entry?

Exclusivity is governed by a combination of patent expiry, FDA exclusivity periods (if applicable), and Orange Book listing status. In glaucoma, the remaining listed patent expiry date is frequently the real gating item for ANDA launch.

What is the exclusivity timeline dynamic for ophthalmic antiglaucoma products?

MoC expiration often clears the primary composition but does not clear formulation or method-of-use.
Listed patent expiry usually governs:
- When Paragraph IV is strategically attractive
- When a generic can launch without enhanced infringement exposure

How do dosing and formulation patents extend market exclusivity?

Once-daily and combination regimens often become protected by:

Method-of-use claims tied to dosing frequency
Formulation claims that support stability and tolerability metrics consistent with label language

Featured-snippet answer: In S01E, the practical exclusivity cliff tends to be the Orange Book “last listed patent” expiry rather than the earliest compound patent expiry.

What is the Orange Book status of ATC S01E antiglaucoma and miotic products?

Orange Book status determines whether FDA-listed patents attach to a specific product and strength. The market impact is direct:

If multiple patents are listed, a generic faces higher “remaining infringement risk,” which raises the likelihood of delay or settlement.

How to read Orange Book listings for S01E?

Key fields that drive decisions:

Drug product active ingredient and strength
Dosage form (solution, suspension)
Applicant/marketing authorization holder
Patent numbers and expiration dates
Patent scope categories (composition, method, formulation)
Indications and “listed for” scope when available

Featured-snippet answer: For S01E, the product-level Orange Book listing structure defines the litigation clock and the earliest launch date for ANDA filers.

Which companies are challenging S01E antiglaucoma patents, and what is the competitive landscape?

The competitive landscape in S01E is typically multi-tier:

Originators with multi-patent estates and fixed-dose combination strategies.
Large generic entrants with ANDA scale and litigation infrastructure.
Specialty ophthalmic brands that prosecute or acquire rights to formulation and method-of-use improvements.

How competitive pressure changes around patent expiry

Months leading to the “first potentially effective date” for generic entry see:
- Aggressive prescribing incentives from originators
- Launch planning and litigation intensification by generics
After settlement or patent expiry:
- Price competition accelerates, especially for single-agent drops
- Combination products retain stronger pricing power longer if fixed-dose patents persist

What formulations are protected in S01E, and what does that mean for “generic-equivalent” eye drops?

Formulation patents are central because ophthalmic tolerability and stability are formulation-dependent.

Which formulation features are most commonly patented?

Preservative system: benzalkonium chloride (BAK) alternatives, reduced BAK, preservative-free containers
Buffer/pH and osmolarity control: optimized for comfort and stability
Viscosity and mucoadhesion: improved residence time
Stabilizers: oxidation control and chemical stability across shelf life
Combination formulation specifics:
- Fixed-dose compatibility of multiple actives
- Particle size and dispersion stability (when applicable)

Generic design-around constraints

Generic filers face a narrower path if:

Listed formulation patents claim specific pH/osmolarity ranges or preservative types.
Method-of-use patents require a dosing regimen that depends on formulation attributes.
Combination products are protected at the fixed-dose level.

What method-of-use and regimen patents matter most in ATC S01E?

S01E method-of-use claims frequently target:

How to treat glaucoma or ocular hypertension
Dosing frequency and treatment goals
Combination therapy structures

What does “regimen” mean in patent terms?

Regimen claims are actionable when they map to:

A label-supported dosing instruction
A specific schedule that the product is marketed for
A combination sequence that aligns with prescribing patterns

Featured-snippet answer: Method-of-use and dosing regimen claims raise infringement exposure even when generics can meet bioequivalence, because they can still practice the claimed method through marketing and administration.

How does S01E compare with other ophthalmic classes on patent durability and generic timing?

Relative to many systemic therapies:

Ophthalmic products often have smaller patient volumes per molecule, but faster substitution dynamics due to payer switching and therapeutic interchange
Patent durability is frequently driven by formulation and method-of-use rather than only MoC
“Multiple strengths, multiple products” patterns create staggered entry points for generics and can fragment price erosion

Featured-snippet answer: S01E’s patent durability is typically less about classic long MoC terms and more about layered formulation and method-of-use listings that remain Orange Book-controlled late.

What generic entry risks exist for S01E antiglaucoma preparations?

Generic launch risk in S01E depends on:

Remaining listed patents at the time of approval/launch
How closely the generic’s formulation matches patented parameters
Whether the originator asserts method-of-use via marketing-to-label theories
Whether settlement restricts launch timing or restricts certain design features

Key risk scenarios

Multiple Orange Book patents block first-launch
- Generic timing shifts to later “designated” dates in settlements
Infringement theories extend beyond formulation
- If method-of-use patents remain, even formulation-adapted generics can face risk.
Residual unlisted patents
- Even without Orange Book listing, some patents can be asserted based on claims that cover the approved generic product.

What biosimilar risks apply in S01E?

Biosimilars generally do not apply to ATC S01E antiglaucoma preparations in the same way as biologics do in other ATC classes. The class is overwhelmingly small-molecule ophthalmic drugs.

Featured-snippet answer: S01E does not present a typical biosimilar-style IP risk profile; the risk drivers are small-molecule patent estates and formulation/method-of-use listings.

Regulatory and lifecycle strategy: How do FDA pathways interact with the S01E patent landscape?

S01E generics are usually evaluated through ANDAs. Regulatory timing interacts with patent status:

The ability to file depends on whether patents are listed and their status.
The ability to launch depends on exclusivity status and whether the generic is subject to an automatic stay or settlement constraints following a Paragraph IV filing.

What matters most for “when can a generic launch”?

FDA approval timing
“Effective date” constraints imposed by patent litigation outcomes
Settlement and court-ordered stays

Key takeaways for investors and licensing teams focused on S01E

The dominant value protection in S01E is typically layered: MoC provides early protection; formulation and method-of-use patents extend late-cycle leverage through Orange Book listing.
Generic entry is most sensitive to the last remaining listed patent expiry, not the earliest compound expiry.
Patent estates in fixed-dose and once-daily ophthalmic products are often the most resilient, because dosing and tolerability depend on formulation-specific attributes.
Paragraph IV filings are attractive only when the remaining listed patent stack is thin or contestable; otherwise settlements commonly translate into delayed launches.

FAQs

What patents most often remain listed near S01E generic launch dates?
How does Orange Book listing scope affect infringement theories for glaucoma eye drops?
Do fixed-dose combination antiglaucoma products face longer patent barriers than single-agent drops?
What types of formulation changes most commonly trigger non-infringement arguments in ophthalmic ANDA cases?
How do dosing frequency and label instructions influence method-of-use patent infringement in S01E?

References (APA)

U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
European Medicines Agency. (n.d.). EPAR and related documents for ophthalmic products by mechanism. https://www.ema.europa.eu/
WHO Collaborating Centre for Drug Statistics Methodology. (n.d.). ATC classification system. https://www.whocc.no/atc/

Drugs in ATC Class S01E

Subclasses in ATC: S01E - ANTIGLAUCOMA PREPARATIONS AND MIOTICS

ATC Class S01E Antiglaucoma Preparations and Miotics: Market Dynamics and Patent Landscape for Eye-Drop Exclusivity, Patent Barriers, and Generic Entry Risk